Collaboration Agreements (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Jun. 28, 2014
Transition Collaborative Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty revenue, percent of net sales	6.50%
Joint Development Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty and licenses revenue	$ 0.8
Minimum [Member] | Transition Collaborative Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential contingent milestone payments	10.0
Minimum [Member] | Joint Development Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential contingent milestone payments	0.5
Minimum [Member] | Upon FDA Approval [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential contingent milestone payments	3.8
Maximum [Member] | Transition Collaborative Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential contingent milestone payments	15.0
Maximum [Member] | Joint Development Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential contingent milestone payments	2.0
Maximum [Member] | Upon FDA Approval [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential contingent milestone payments	$ 5.5